Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Interventional closure of patent foramen ovale (PFO) associates with reduced risk of stroke recurrence in patients with cryptogenic ischemic stroke as reported in the recent CLOSE and REDUCE trials. The long-term follow-up results of the RESPECT and DEFENSE-PFO trial confirmed these findings. PFO closure is therefore recommended in patient with cryptogenic ischemic stroke and PFO according to the current German interdisciplinary guidelines. It is likely that the number of PFO closure procedures will increase significantly in the near future. However, new onset atrial fibrillation (AF) appears to increase in patients following this procedure. In the REDUCE study, new onset atrial fibrillation was detected in 6.6% patients in the PFO closure group compared with 0.4% in the control group (medical treatment); 59% of these patients were diagnosed within the first two weeks following the procedure and 83% within 45 days, respectively. These results were consistent with the CLOSE study: AF was detected in 4.6% patients in the intervention group vs. 0.9% in the control group. Up until today, markers to identify and quantify the individual risk of AF onset are lacking. Furthermore, under-reporting and under-detection of AF occurrence after PFO closure is likely. This study is designed to to assess the prevalence and and identification of electrophysiological and echocardiographic parameters of new-onset AF.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PFO closure | Active Comparator | Patients with embolic stroke of undetermined source (ESUS) with patent foramen ovale (PFO) eligible for interventional PFO occlusion receiving a structured electrophysiological study due to palpitations before the PFO closure. Extensive cardiac monitoring. |
|
| NO PFO | No Intervention | Patients with embolic stroke of undetermined source (ESUS) with NO patent foramen ovale (PFO) receiving a structured electrophysiological study due to palpitations. Extensive cardiac monitoring. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PFO closure | Procedure | Interventional closure of a patent foramen oval preceded by an electrophysiological study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in baseline heart rhythm, e.g. new-onset atrial fibrillation | Rate of detection of new-onset atrial fibrillation with Holter and loop recorder monitoring after electrophysiological study | 1, 3, 6, 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study | Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation | 1 month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitätsklinikum des Saarlandes | Recruiting | Homburg | Saarland | 66421 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054092 | Foramen Ovale, Patent |
| ID | Term |
|---|---|
| D006344 | Heart Septal Defects, Atrial |
| D006343 | Heart Septal Defects |
| D006330 | Heart Defects, Congenital |
| D018376 | Cardiovascular Abnormalities |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study | Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation | 3 months |
| Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study | Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation | 6 months |
| Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study | Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation | 12 months |
| Change in left atrial morphology (LA volume index) following PFO closure | Assessment of the change in left atrial morphology and function (LA volume index) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA volume index, physiologocal parameter | 1 month |
| Change in left atrial function (LA strain) following PFO closure | Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter | 1 month |
| Change in new-onset AF following PFO closure | Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG | 1 month |
| Change in left atrial morphology (LA volume index) following PFO closure | Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter | 3 months |
| Change in left atrial function (LA strain) following PFO closure | Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter | 3 months |
| Change in new-onset AF following PFO closure | Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG | 3 months |
| Change in left atrial morphology (LA volume index) following PFO closure | Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter | 6 months |
| Change in left atrial function (LA strain) following PFO closure | Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter | 6 months |
| Change in new-onset AF following PFO closure | Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG | 6 months |
| Change in left atrial morphology (LA volume index) following PFO closure | Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter | 12 months |
| Change in left atrial function (LA strain) following PFO closure | Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter | 12 months |
| Change in new-onset AF following PFO closure | Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG | 12 months |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |